Silica cages help anti-cancer antibodies prevent tumour growth in mice

May 22nd, 2010 - 1:25 pm ICT by ANI  

Washington, May 22 (ANI): If anti-cancer drugs are packed into honeycombed particles of chemically modified silica, they can improve the drugs’ ability to fight skin cancer in mice, according to new research.

The study showed that the caged structure could help anti-cancer antibodies prevent tumour growth and prolong the lives of mice.

“We are very excited by our preliminary results. We plan to do some additional, larger studies with animals. We hope the results hold up well enough to take it to clinical trials somewhere down the road,” said biochemist Chenghong Lei of the Department of Energy’s Pacific Northwest National Laboratory, part of the team of PNNL and University of Washington scientists.

Anti-cancer antibodies are some of the most promising types of cancer therapies.

The antibodies target a particular protein on cancer cells and - in a poorly understood way - kill off the cells. Examples include herceptin for one form of breast cancer and cetuximab for colon cancer.

However, unlike popping a pill, antibody-based treatments require patients to go in for intravenous drips into the arm.

These sessions cost time and money, and expose healthy tissue to the antibody, causing side effects.

Packaging antibodies into particles would concentrate them at the tumor and possibly reduce side effects.

Other research has shown silicon to be well tolerated by cells, animals and people.

Thus, in collaboration with tumour biologist Karl Erik Hellstrom’s group at UW, the scientists explored particles made from material called mesoporous silica against cancer in mice.

“The silica’s mesoporous nature provides honeycomb-like structures that can pack lots of individual drug molecules. We’ve been exploring the material for our energy and environmental problems, but it seemed like a natural fit for drug delivery,” said PNNL material scientist Jun Liu.

In previous work, the team created particles that contain nano-sized hexagonal pores that hold antibodies, enzymes or other proteins.

In addition, adorning the silica pores with small chemical groups helps trap proteins inside.

However, not permanently - these proteins slowly leak out like a time-release capsule.

To test whether anti-cancer antibodies packaged in modified mesoporous silica would be more effective against tumours than free-flowing antibodies, they first chemically modified mesoporous silica particles of about six to 12 micrometers (about 1/10 the diameter of human hair).

These particles contained pores of about 30 nanometers in diameter. They found that the extent and choice of chemical modification - amine, carboxylic acid or sulfonic acid groups - determined how fast the antibodies leaked out, a property that can be exploited to fine tune particles to different drugs.

Additional biochemical tests showed that the antibodies released from the silica cages appeared to be structurally sound and worked properly.

They then tested the particles in mouse tumours at UW, filling them with an antibody called anti-CTLA4 that fights many cancers, including melanoma, a skin cancer. The team injected these packaged antibodies into mouse tumours.

The team also injected antibodies alone or empty particles in other mouse tumours.

The packaged antibodies slowed the growth of tumours the best.

The study has been published in the Journal of the American Chemical Society online. (ANI)

Related Stories

Tags: , , , , , , , , , , , , , , , , , , ,

Posted in Health Science |

Subscribe